Literature DB >> 19772823

Certolizumab pegol in active rheumatoid arthritis.

Aarat M Patel1, Larry W Moreland.   

Abstract

Entities:  

Year:  2009        PMID： 19772823      PMCID： PMC3741093          DOI： 10.1007/s11926-009-0056-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  5 in total

1.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

2.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Authors:  Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2004-05

3.  Maintenance therapy with certolizumab pegol for Crohn's disease.

Authors:  Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

4.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Authors:  J Smolen; R B Landewé; P Mease; J Brzezicki; D Mason; K Luijtens; R F van Vollenhoven; A Kavanaugh; M Schiff; G R Burmester; V Strand; J Vencovsky; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

5.  Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Authors:  R Fleischmann; J Vencovsky; R F van Vollenhoven; D Borenstein; J Box; G Coteur; N Goel; H-P Brezinschek; A Innes; V Strand
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.